Recursion Pharmaceuticals (RXRX) Stock Price
$4.94 0%
to add to portfolio
AI Score
-
Alternative
6 -
Fundamental
3 -
Technical
4
Our AI score evaluates a company's performance on a scale from 0 to 10 by analyzing alternative data points — web traffic, app downloads, job postings, etc - along with financial health and technical signals. Scores below 4 project bearish performance, while scores above 6 project bullish performance.
Sign up to get access to more historical data and insights on Recursion Pharmaceuticals, AI stock picks, stock alerts and much more.
RXRX AI Stock Analysis
Financial Performance
Recursion Pharmaceuticals reported a revenue of $14.7M in the last quarter, marking an increase of 226.9% from the previous quarter and a slight rise of 2.3% year over year. Despite this growth in revenue, their gross profit was -$7.1M, indicating a significant loss compared to previous quarters and years (up by 14.5% from the last quarter but down by -637.5% YoY). Their operating income also suffered, with a loss of -$191.4M (down by -4.1% QoQ and -90.3% YoY). The EBITDA ratio stands at -12.98 which indicates poor operational profitability.
Stock Price
The company's stock is currently trading at $5.77, showing an increase of 10.5% over the past month but decreasing by -14.4% YoY which suggests volatility in its performance throughout the year.The RSI value is currently at a neutral level of 54.35 while its PE ratio stands at -3.19 indicating that it may be undervalued.
Alternative Data Signals
The company's web traffic has seen positive growth with an estimated monthly visitor count of 72205 (up by 4.9% MoM and up by 50.9% YoY). However, job openings have decreased slightly (-9..7%) suggesting potential scaling back on hiring or expansion efforts.Recursion Pharmaceuticals' social media presence is growing steadily with Twitter followers increasing dramatically by73 .9 % in the last three months.The business outlook as reported by employees appears mixed with only53 % expressing positivity.
Conclusion
Considering the company's financial performance, stock price trends, and alternative data signals, the analysis for Recursion Pharmaceuticals' stock appears bearish. Despite some positive signs in revenue growth and social media presence, the significant losses in gross profit and operating income along with a decrease in job openings suggest potential challenges ahead.
Note: This AI Stock Analysis is based on data as of August 16. Our members can refresh and get access to an up-to-date AI stock analysis.
Sign up
Recursion Pharmaceuticals (RXRX) Price Prediction
Based on a combination of financial analysis, technical indicators, and insights from alternative data, we predict that the stock price of Recursion Pharmaceuticals (RXRX), currently trading at $4.94, will... Sign up to access price prediction.
Disclaimer:
This prediction is provided for informational purposes only and does not constitute financial advice. Market conditions are subject to change, and past performance is not indicative of future results. Please conduct your own research or consult a professional before making investment decisions.
About RXRX
-
Recursion Pharmaceuticals, Inc.
-
Symbol
RXRX
-
Market
NASDAQ
-
Industry
Biotechnology
-
Market Cap
2.1B
Similar Stocks
 |
Catalyst Pharmaceuticals CPRX |
$21.08 2.5% |
8 |
 |
Inovio Pharmaceuticals INO |
$1.96 2.6% |
3 |
 |
Moderna MRNA |
$27.12 3.4% |
3 |
 |
Anavex Life Sciences AVXL |
$9.53 0.2% |
5 |
 |
BridgeBio Pharma BBIO |
$49.08 2.3% |
6 |
News
RXRX Alternative Data
Web Traffic
Recursion Pharmaceuticals receives an estimated 72205 monthly visitors to recursion.com.
-
Web Traffic
72205
-
Change from Previous Month
4.9%
-
3 Month Change
54.7%
-
YoY Change
54.7%
Facebook Engagement
Recursion Pharmaceuticals has engaged 39 users via their Facebook Page over the last 7 days.
-
Facebook Engagement
39
-
Daily Change
225%
-
1 Month Change
333.3%
-
3 Month Change
254.5%
-
YoY Change
254.5%
Youtube Subscribers
Recursion Pharmaceuticals has 10,600 subscribers on its main Youtube channel, up by 168.4% over the last month.
-
Youtube Subscribers
10600
-
Daily Change
2.9%
-
1 Month Change
168.4%
-
3 Month Change
182.7%
-
YoY Change
182.7%
Job Postings
Recursion Pharmaceuticals currenly has an estimated 30 open job postings.
-
Job Postings
30
-
Daily Change
3.2%
-
1 Month Change
0%
-
3 Month Change
130.8%
-
YoY Change
130.8%
Reddit Mentions
Recursion Pharmaceuticals has been mentioned an estimated 0 times in investment subreddits on Reddit over the last 24 hours.
-
Reddit Mentions
0
-
Daily Change
0%
-
1 Month Change
100%
-
3 Month Change
0%
Twitter Followers
Recursion Pharmaceuticals has 15,165 Twitter Followers on its main Twitter (also known as X) account, which is up by 1.7% over the last month.
-
Twitter Followers
15165
-
Daily Change
0.2%
-
1 Month Change
1.7%
-
3 Month Change
6.3%
-
YoY Change
6.3%
Business Outlook
According to employee reviews, the business outlook among employees at Recursion Pharmaceuticals is 53 out of 100 (neutral).
-
Business Outlook
53
-
Change from Previous Month
10.2%
-
3 Month Change
29.3%
-
YoY Change
29.3%
News Mentions
Recursion Pharmaceuticals was mentioned 1 times in the news yesterday.
-
News Mentions
1
-
Daily Change
0%
-
1 Month Change
0%
-
3 Month Change
0%
LinkedIn Employees
According to LinkedIn, Recursion Pharmaceuticals has 580 employees.
-
LinkedIn Employees
580
-
Daily Change
2%
-
1 Month Change
0%
-
3 Month Change
0%
-
YoY Change
0%
RXRX Financials
RXRX Key Metrics
-
Total Revenue
$14.7M
-
Net Income
-$202.5M
-
Earnings per Share
-$0.5
-
Free cash flow
-$133.8M
-
EBITDA
-$191.4M
-
EBITDA Ratio
-12.9785
-
Total Assets
$1.3B
RXRX 2-year Revenue & Income
RXRX 2-year Free Cash Flow
RXRX Technicals
RXRX SMA
RXRX RSI
FAQ
What's the current price of Recursion Pharmaceuticals (RXRX) Stock?
The price of an Recursion Pharmaceuticals (RXRX) share is $4.94.
What's the market cap of Recursion Pharmaceuticals?
The current market cap of Recursion Pharmaceuticals is 2.1B.
Should I buy or sell RXRX?
Recursion Pharmaceuticals shows several positive indicators, but they aren’t strong enough to warrant a buy recommendation. At its current price, Recursion Pharmaceuticals is better viewed as a hold or accumulate position while waiting for further developments.
Is Recursion Pharmaceuticals a good investment?
The current analysis of Recursion Pharmaceuticals' fundamentals, technical aspects, and alternative data insights indicates a neutral outlook on the stock. While there are promising elements in Recursion Pharmaceuticals' portfolio, the presence of equal risks and opportunities suggests that it might not drive significant gains or losses at this moment.
Is now a good time to buy Recursion Pharmaceuticals (RXRX) Stock?
Based on an analysis that includes fundamentals, technical analysis, and alternative data insights, the outlook for Recursion Pharmaceuticals stock is currently neutral, suggesting a cautious approach might be wise.
What are some stocks similar to Recursion Pharmaceuticals (RXRX) that investors often compare it to?
Recursion Pharmaceuticals (RXRX) is often compared to similar stocks such as Catalyst Pharmaceuticals, Inovio Pharmaceuticals, Moderna, Anavex Life Sciences and BridgeBio Pharma.
What is the forecast for Recursion Pharmaceuticals' stock price in 2026?
Using a mix of financial analysis, technical indicators, and alternative data, we forecast Recursion Pharmaceuticals' stock price to be around $4.86 in 2026. Starting from the current price of $4.94, this represents a 1.7% change in price, indicating a neutral outlook for the stock.
How to buy Recursion Pharmaceuticals (RXRX) Stock?
Recursion Pharmaceuticals stock is available for purchase through numerous brokerage firms, including online platforms. Investors can also buy Recursion Pharmaceuticals shares via trading apps on their smartphones or by utilizing services like robo-advisors for automated investing.